蔚來(09866.HK)反擊沽空報告 稱公司信息遭誤讀
蔚來(09866.HK)(NIO.US)遭沽空機構Grizzly Research狙擊,蔚來表示,該份沽空報告充滿大量不實信息以及對公司披露信息的誤讀,強調公司一直嚴格遵守上市公司相關準則,目前已就該份報告啟動相關程序。
Grizzly Research指控蔚來利用威朗製藥(Valeant Pharmaceuticals)類似的會計遊戲,通過誇大收入及提高淨利潤率來達到目標。報告稱,蔚來透過未合併的關聯方武漢蔚能來誇大收入及盈利能力,稱武漢蔚能協助蔚來持續實現高增長及盈利預期,並且已經為蔚來創造數十億美元的收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.